Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 54 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BIOCLIN CONSULTING & MARKETING from Sint-Pieters-Leeuw, company number BE0475753623, closed financial year 2025 with a result of € 27,144 after tax. For that financial year BIOCLIN CONSULTING & MARKETING recorded revenue of € 244,475 and equity of € 61,326. Compared with financial year 2024, the result moved from € 23,179 to € 27,144. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.
€ 61,326
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 27,144
▲ 17% vs 2024
Profit after tax over the fiscal year.
€ 13,807
▼ 87% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 27,000 paid out
99 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 4,452
▼ 41% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 89,804
▼ 24% vs 2024
€ 29,812 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 12,533
▼ 73% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 4,750
▲ € 4,200 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 207,160 | € 222,065 | € 222,095 | € 244,475 | ▲ 10% |
| Gross margin | € 4,123 | € 10,488 | € 39,220 | € 64,372 | ▲ 64% |
| Profit after taxes | € -508 | € 2,727 | € 23,179 | € 27,144 | ▲ 17% |
| Equity | € 59,276 | € 62,003 | € 61,182 | € 61,326 | |
| Total debts | € 46,011 | € 53,727 | € 190,216 | € 134,087 | ▼ 30% |
| Cash | € 4,303 | € 16,612 | € 108,609 | € 13,807 | ▼ 87% |
| Retained profit | € 40,676 | € 43,403 | € 40,722 | € 40,866 | |
| Dividend | € 0 | € 0 | € 24,000 | € 27,000 | ▲ 13% |
| Bank debt | € 0 | € 0 | € 118,640 | € 89,804 | ▼ 24% |
| Balance sheet total | € 105,287 | € 115,730 | € 251,398 | € 195,413 | ▼ 22% |
Key figures of BIOCLIN CONSULTING & MARKETING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIOCLIN CONSULTING & MARKETING?
What happened at BIOCLIN CONSULTING & MARKETING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 27,144 (▲ 17% vs 2024). filed late Source: NBB ↗
- New establishment in Sint-Pieters-Leeuw. KBO
- Start of the company according to the CBE. KBO
In short
From € 508 loss in 2022 to € 27,144 profit in 2025.
Paid € 8,045 in corporate taxes since 2022.
Best year ever: 2025, with € 27,144 profit.
Paid out € 51,000 in dividends to the owners in total.
Establishments
Establishment units
Physical locations of this company
Meerweg 119
1601 Sint-Pieters-Leeuw
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0475.753.623
- VAT number
- BE 0475.753.623
- Registered office
- Meerweg 119, 1601 Sint-Pieters-Leeuw
- Names & denominations
- BIOCLIN CONSULTING & MARKETING
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 October 2001
- Peppol
- Active · Active since 14 Jan 2026
- Activities · NACE
Activiteiten op het gebied van voeding
Overige activiteiten i.v.m. gezondheidszorg, n.e.g.
Overige menselijke gezondheidszorg, n.e.g.